– Clinical observations from preliminary data at the lowest dose of MGTA-117 in a Phase 1/2 clinical trial indicate target binding, reduction of target cells in bone marrow, rapid drug clearance and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback